Development of MCM-41 mesoporous silica nanoparticles as a platform for pramipexole delivery

Add time:08/20/2019    Source:sciencedirect.com

Herein, we present development of new pH-responsive drug delivery systems for D3-dopamine receptor agonist pramipexole, based on its encapsulation in MCM-41 mesoporous silica particles. Pramipexole loaded particles were further coated with chitosan and/or sodium alginate in order to modify drug release. The prepared pramipexole loaded nanoparticles were characterized by using X-ray diffraction (XRD), N2-physisorption, dynamic light scattering (DLS), TEM and attenuated total reflection infrared (ATR-FTIR) spectra. The post-coating of pramipexole loaded MCM-41 with chitosan/sodium alginate polymers changed dramatically physicochemical properties of the particles. The release profile showed that combination of both polymers led to significant reduction by approximately 50% in the initial burst-release effect at both tested pH values (1.2 and 6.8). Uncoated MCM-41 released the total amount of pramipexole within the first 15 min, whereas double-coated particles reached full release after 300 min. Interestingly, we found that pramipexole loaded MCM-41 particles showed a higher potential in preventing H2O2-induced oxidative damage in human neuroblastoma SH-SY5Y cells, compared to the free drug. In conclusion, pramipexole loading in chitosan/sodium alginate coated MCM-41 might represent a promising drug delivery strategy for modified release and neuronal protection against oxidative damage, observed in Parkinson's disease.

We also recommend Trading Suppliers and Manufacturers of Pramipexole dihydrochloride (cas 104632-25-9). Pls Click Website Link as below: cas 104632-25-9 suppliers

Prev:Validated chiral liquid chromatographic method for the enantiomeric separation of Pramipexole dihydrochloride (cas 104632-25-9) monohydrate
Next:Pramipexole (cas 104632-26-0) nanocrystals for transdermal permeation: Characterization and its enhancement micro-mechanism)